학술논문
P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: A SUBGROUP ANALYSIS FROM THE GMMG-HD7 TRIAL
Document Type
article
Author
E. K. Mai; U. Bertsch; R. Fenk; D. Tichy; B. Besemer; J. Dürig; R. Schroers; I. von Metzler; M. Hänel; C. Mann; A. M. Asemissen; B. Heilmeier; E. Nievergall; S. Huhn; K. Kriegsmann; N. Weinhold; S. Luntz; T. A. W. Holderrried; K. Trautmann-Grill; D. Gezer; M. Klaiber-Hakimi; M. Müller; C. Khandanpour; W. Knauf; C. Scheid; M. Munder; T. Geer; H. Riesenberg; J. Thomalla; M. Hoffmann; M. S. Raab; H. J. Salwender; K. C. Weisel; H. Goldschmidt
Source
HemaSphere, Vol 6, Pp 820-821 (2022)
Subject
Language
English
ISSN
2572-9241